Compare RRGB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | ATYR |
|---|---|---|
| Founded | 1969 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 69.2M |
| IPO Year | 2002 | N/A |
| Metric | RRGB | ATYR |
|---|---|---|
| Price | $3.68 | $1.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $9.67 | $4.20 |
| AVG Volume (30 Days) | 179.4K | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,315,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.50 | $0.64 |
| 52 Week High | $7.52 | $7.29 |
| Indicator | RRGB | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 63.98 |
| Support Level | $3.20 | $0.67 |
| Resistance Level | $4.42 | $1.08 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 66.67 | 70.38 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.